At a glance

ClinicalIndex Comparison Record

Phase 1Completed· 43 enrolled

Drug / intervention

PF-03732010drug

Likely dose

PF-03732010 0.5 mg/kgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00557505

NCT00557505Phase 1Completed

Compare CT.gov

A Phase 1 Pharmacokinetic And Pharmacodynamic Study Of PF-03732010 In Patients With Advanced Solid Tumors

Pfizer·interventional·Posted Nov 14, 2007·Updated Mar 26, 2012

In Brief

A Phase 1 clinical trial evaluating PF-03732010 for Neoplasms. Completed, enrolled 43 participants across 3 sites in 3 countries.

Detailed Summary

P-cadherin may play a part in tumor growth; PF-03732010 is a new drug that inhibits P-cadherin. This study will test how well the drug is tolerated, and what effects there might be. Blood will also be taken to measure the amount of drug in blood.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsNeoplasms

CountriesAustralia, South Korea, United States

Collaborators--

Timeline

Phase 1CompletedFinished

20082009201020112012201320142015201620172018201920202021202220232024202520262027

First PostedNov 2007

Enrollment StartDec 2007

Primary CompletionFeb 2011

TodayJul 2026

First PostedNov 14, 2007

Enrollment StartDec 1, 2007

Primary CompletionFeb 1, 2011

TodayJul 2, 2026

Enrollment to primary: 3.2 yearsPosted 18.6 years ago

Interventions

PF-03732010drug

IV infusion. Escalating dose levels, starting at 0.5 mg/kg to Maximum Tolerated Dose. Cycle length of 4 weeks for first cycle, and 2 weekly for subsequently cycles was originally explored, yet based on emerging PK data the Cycle 1 duration is 2 weeks and then weekly. Number of Cycles: Until Progression or unacceptable toxicity develops.